Spots Global Cancer Trial Database for metastatic castration resistant prostate cancer
Every month we try and update this database with for metastatic castration resistant prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Abiraterone Acetate in Combination With Tildrakizumab | NCT04458311 | Metastatic Cast... | Abiraterone Ace... Tildrakizumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | NCT03570619 | Metastatic Cast... Metastatic Canc... Solid Tumor | Nivolumab Ipilimumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | NCT05369000 | Metastatic Cast... | LAVA-1207 LAVA-1207 plus ... | 18 Years - | Lava Therapeutics | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00910754 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | NCT04634344 | Metastatic Cast... | DZD2269 | 18 Years - | Dizal Pharmaceuticals | |
| Abiraterone Acetate in Combination With Tildrakizumab | NCT04458311 | Metastatic Cast... | Abiraterone Ace... Tildrakizumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01017939 | Prostate Neopla... | Abiraterone ace... Prednisone Dextromethorpha... Theophylline | 18 Years - | Janssen Research & Development, LLC | |
| PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. | NCT02787837 | Advanced Prosta... Abiraterone ACe... | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05241613 | Metastatic Cast... | AC176 | 18 Years - | Accutar Biotechnology Inc | |
| Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). | NCT05219500 | Metastatic Cast... | FPI-2265 | 18 Years - | Fusion Pharmaceuticals Inc. | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response | NCT02471469 | Metastatic Cast... | Enzalutamide, 1... | 18 Years - | Radboud University Medical Center | |
| Prostate Cancer Biobank | NCT04024475 | Prostatic Neopl... | Observation | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) | NCT03658447 | Metastatic Cast... | Pembrolizumab 177Lu-PSMA | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | NCT03752099 | Metastatic Cast... | VERU-111 | 18 Years - | Veru Inc. | |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | NCT03706365 | Prostate Cancer | Abemaciclib Abiraterone Ace... Prednisone Placebo | 18 Years - | Eli Lilly and Company | |
| A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | NCT03776968 | Metastatic Cast... | HC1119 | 18 Years - 45 Years | Hinova Pharmaceuticals Inc. | |
| A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01017939 | Prostate Neopla... | Abiraterone ace... Prednisone Dextromethorpha... Theophylline | 18 Years - | Janssen Research & Development, LLC | |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | NCT06084338 | Prostate Cancer | stereotactic ab... Pluvicto topical testost... | 18 Years - | VA Office of Research and Development | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Prostate Cancer Biobank | NCT04024475 | Prostatic Neopl... | Observation | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | NCT05124795 | Metastatic Cast... | IMU-935 | 18 Years - | Immunic AG | |
| A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | NCT03778047 | Metastatic Cast... | Enzalutamide HC1119 | 18 Years - | Hinova Pharmaceuticals Inc. | |
| Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | NCT04056754 | Metastatic Cast... | Abiraterone Ace... Placebo Prednisone | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer | NCT02991911 | Metastatic Cast... | MEDI3726 Post-C... MEDI3726 Pre-Ch... MEDI3726 & Enza... | 18 Years - 100 Years | MedImmune LLC | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy | NCT02121639 | Prostate Cancer | Placebo AZD5363 | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy | NCT02121639 | Prostate Cancer | Placebo AZD5363 | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | NCT03774056 | Metastatic Cast... | HC-1119 | 18 Years - | Hinova Pharmaceuticals Inc. | |
| Optimizing Abiraterone Therapy | NCT02426333 | Metastatic Cast... | Abiraterone Ace... | 18 Years - | Radboud University Medical Center | |
| Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | NCT02566772 | Metastatic Cast... | TAS3681 | 18 Years - | Taiho Oncology, Inc. | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | NCT03531827 | Metastatic Cast... Prostate Neopla... | enzalutamide CRLX101 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone | NCT02288247 | Metastatic Cast... | Enzalutamide Docetaxel Prednisolone Placebo | 18 Years - | Astellas Pharma Inc | |
| Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | NCT01591122 | Prostate Cancer | Placebo and pre... Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | NCT04056754 | Metastatic Cast... | Abiraterone Ace... Placebo Prednisone | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer | NCT02991911 | Metastatic Cast... | MEDI3726 Post-C... MEDI3726 Pre-Ch... MEDI3726 & Enza... | 18 Years - 100 Years | MedImmune LLC | |
| Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy | NCT03042312 | Metastatic Cast... | 177Lu-PSMA-617 | 18 Years - | Endocyte | |
| Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide | NCT02130947 | Metastatic Cast... | Exercise | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | NCT03641560 | Metastatic Cast... | Enzalutamide Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | NCT06084338 | Prostate Cancer | stereotactic ab... Pluvicto topical testost... | 18 Years - | VA Office of Research and Development | |
| A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00910754 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | NCT01591122 | Prostate Cancer | Placebo and pre... Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | NCT04634344 | Metastatic Cast... | DZD2269 | 18 Years - | Dizal Pharmaceuticals | |
| European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT02495974 | Metastatic Cast... | enzalutamide | - | Astellas Pharma Inc | |
| A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | NCT04869488 | Metastatic Cast... | Fluzoparib Enzalutamide OR... Fluzoparib Comb... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | NCT04104893 | Metastatic Cast... | Pembrolizumab | 18 Years - | VA Office of Research and Development | |
| A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer | NCT01541007 | Metastatic Cast... | Cabazitaxel weekly cabazita... | 18 Years - | Karolinska University Hospital | |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | NCT04104893 | Metastatic Cast... | Pembrolizumab | 18 Years - | VA Office of Research and Development | |
| Optimizing Abiraterone Therapy | NCT02426333 | Metastatic Cast... | Abiraterone Ace... | 18 Years - | Radboud University Medical Center | |
| IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | NCT05124795 | Metastatic Cast... | IMU-935 | 18 Years - | Immunic AG | |
| To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | NCT03752099 | Metastatic Cast... | VERU-111 | 18 Years - | Veru Inc. | |
| A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer | NCT03822871 | Prostate Cancer | CTT1403 CTT1057 68Ga-PSMA-11 | 18 Years - | Cancer Targeted Technology | |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | NCT06084338 | Prostate Cancer | stereotactic ab... Pluvicto topical testost... | 18 Years - | VA Office of Research and Development | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. | NCT02787837 | Advanced Prosta... Abiraterone ACe... | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation | NCT04486937 | Metastatic Cast... | S410914 tablet | 18 Years - | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | NCT03454451 | Non-Small Cell ... Renal Cell Canc... Colorectal Canc... Triple Negative... Cervical Cancer Ovarian Cancer Pancreatic Canc... Endometrial Can... Sarcoma Squamous Cell C... Bladder Cancer Metastatic Cast... Non-hodgkin Lym... | CPI-006 CPI-006 + cifor... CPI-006 + pembr... CPI-006 CPI-006 + cifor... CPI-006 + pembr... | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | NCT02566772 | Metastatic Cast... | TAS3681 | 18 Years - | Taiho Oncology, Inc. | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05673109 | Metastatic Cast... | AC176 | 18 Years - | Accutar Biotechnology Inc | |
| A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment | NCT02441517 | Metastatic Cast... | Enzalutamide | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
